TGFB1 and metabolic dysfunction-associated steatohepatitis: This positive result inspired researchers to conduct a randomized double-blind placebo-controlled study in 52 patients with non-alcoholic steatohepatitis (NASH), patients were evaluated for liver stiffness and liver fibrosis biomarkers including hyaluronic acid (HA) and transforming growth factor beta-1 (TGF-β1) before and 12 weeks after treatment with montelukast or placebo, and showed that montelukast significantly reduced the values of liver stiffness measurement and levels of HA and TGF-β1 (Abdallah et al., 2021).